EUVIMEDEUVIMED entdecken
Crossref

Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1696b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Cantharidin, Molluscum Contagiosum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved cantharidin 0.7% solution (Ycanth – Verrica) for topical treatment of molluscum contagiosum in patients ≥2 years old. Ycanth was the first drug to be approved in the US for this indication. A 10.3% gel formulation of berdazimer (Zelsuvmi), a nitric oxide-releasing agent, has also been approved by the FDA for treatment of molluscum contagiosum (in patients ≥1 year old); it will be reviewed in a future issue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CantharidinMolluscum ContagiosumHumans

Stichwörter der Autor:innen

YcanthZelsuvmiadverse effectsberdazimercantharidindosageefficacylactationmolluscum contagiosumpregnancysafety

Substanzen

Cantharidin

Zitieren

APA

(2024). Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1696b

Vancouver

Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1696b

BibTeX
@article{euvimed2024,
  title = {Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1696b}
}
Kostenlos starten →